— Received Notice from the FDA that the SYN-004 (ribaxamase) Phase 1b/2a Clinical Program in Adult Allogeneic HCT Recipients May Proceed as Planned; Trial Commencement Anticipated in Q1 2021 — — Received Study-May-Proceed Letter from the FDA Supporting a Phase 1 Single Ascending Dose Study of SYN-020 IAP; Phase 1 Study to Support Development of […]
— Announced FDA Clearance of IND Application for SYN-020 Intestinal Alkaline Phosphatase (IAP) — — Signed Option License Agreement with Massachusetts General Hospital to Develop SYN-020 to Treat and Prevent Metabolic and Inflammatory Diseases Associated with Aging — — Enrollment in the Phase 2b Investigator-Sponsored Clinical Trial of SYN-010 Has Recommenced Following COVID-19-Related Postponement —
— Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., May 5, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas
— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results Read More »
— Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US — ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office
— Announced Clinical Trial Agreement with Washington University School of Medicine to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients — — Conference Call Today, August 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company
— Conference Call Scheduled for Thursday, August 8, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the Company intends to release its operational highlights
— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results Read More »
— Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs — — Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ — Synthetic Biologics,
— SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 — — Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) — ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome
